Regulation of glucose metabolism using anti-CGRP antibodies
US12122821B2 · kind B2 · utility
Assignee
Inventors
Key dates
| Filing date | Jul 12, 2019 |
| Grant date | Oct 22, 2024 |
| Priority date | — |
| Expiry date | Sep 15, 2040 |
Classification
- Technology area (CPC G)Physics
- CPC primaryG01N2333/5753
- WIPO fieldMeasurement
- WIPO sectorInstruments
Abstract
The present disclosure provides methods for the prevention or treatment of metabolic disorders. In exemplary embodiments, methods of administering an anti-CGRP antibody are provided, optionally in combination with a second agent, wherein peripheral and/or hepatic glucose utilization is increased, thereby preventing or treating diseases and disorders associated with insulin resistance. Compositions comprising an anti-CGRP antibody are also provided, optionally in combination with a second agent, which are suitable for administration to increase peripheral and/or hepatic glucose utilization and thereby prevent or treat diseases and disorders associated with insulin resistance.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.